Genetics

Mesoblast (Nasdaq:MESO) announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product candidate MSC-100-IV (remestemcel-L) in children with steroid refractory acute Graft versus Host Disease (aGVHD) has successfully met the primary endpoint of Day 28 overall response (OR, complete + partial response) rate. As quoted in the press release: In the 55 …

Mesoblast (Nasdaq:MESO) announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product candidate MSC-100-IV (remestemcel-L) in children with steroid refractory acute Graft versus Host Disease (aGVHD) has successfully met the primary endpoint of Day 28 overall response (OR, complete + partial response) rate.

As quoted in the press release:

In the 55 children enrolled in Mesoblast’s open-label Phase 3 trial conducted across 32 sites in the United States, the Day 28 OR rate was 69%, a statistically significant increase compared to the protocol-defined historical control rate of 45% (p=0.0003).

Among patients who received at least one treatment infusion and were followed up for 100 days (n=50), the mortality rate was 22%. This is in contrast to Day 100 mortality rates as high as 70% in patients who fail to respond to initial steroid therapy1,2,3.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21205.16-69.41
TSXV900.87+10.01
DOW35028.65-339.82
S&P 5004532.76-44.35
NASD14340.26-166.64
ASX7332.50-76.30

COMMODITIES

Commodities
Gold1838.56+0.14
Silver24.20+0.12
Copper4.52+0.05
Palladium2071.50+91.00
Platinum1047.00+30.00
Oil86.79-0.17
Heating Oil2.62-0.02
Natural Gas4.01-0.03

DOWNLOAD FREE REPORTS

×